BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35074476)

  • 1. Economic evaluation of long-term albumin use in cirrhosis patients from the Mexican healthcare system perspective.
    Moctezuma-Velazquez C; Castro-Narro G; Simó P; Viayna E; Aceituno S; Soler M; Torre A
    Ann Hepatol; 2022; 27(2):100673. PubMed ID: 35074476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALBUMIN VERSUS STANDARD MEDICAL TREATMENT IN BRAZILIAN PUBLIC AND PRIVATE HEALTHCARE SYSTEMS.
    Terra C; Viayna E; Ayzin L; Fuster C; Aceituno S; Tafla C
    Arq Gastroenterol; 2023; 60(3):356-363. PubMed ID: 37792766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.
    Caraceni P; Riggio O; Angeli P; Alessandria C; Neri S; Foschi FG; Levantesi F; Airoldi A; Boccia S; Svegliati-Baroni G; Fagiuoli S; Romanelli RG; Cozzolongo R; Di Marco V; Sangiovanni V; Morisco F; Toniutto P; Tortora A; De Marco R; Angelico M; Cacciola I; Elia G; Federico A; Massironi S; Guarisco R; Galioto A; Ballardini G; Rendina M; Nardelli S; Piano S; Elia C; Prestianni L; Cappa FM; Cesarini L; Simone L; Pasquale C; Cavallin M; Andrealli A; Fidone F; Ruggeri M; Roncadori A; Baldassarre M; Tufoni M; Zaccherini G; Bernardi M;
    Lancet; 2018 Jun; 391(10138):2417-2429. PubMed ID: 29861076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites.
    Di Pascoli M; Fasolato S; Piano S; Bolognesi M; Angeli P
    Liver Int; 2019 Jan; 39(1):98-105. PubMed ID: 30230204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites.
    Caraceni P; Tufoni M; Zaccherini G; Riggio O; Angeli P; Alessandria C; Neri S; Foschi FG; Levantesi F; Airoldi A; Simone L; Svegliati-Baroni G; Fagiuoli S; Laffi G; Cozzolongo R; Di Marco V; Sangiovanni V; Morisco F; Toniutto P; Gasbarrini A; De Marco R; Piano S; Nardelli S; Elia C; Roncadori A; Baldassarre M; Bernardi M;
    J Hepatol; 2021 Feb; 74(2):340-349. PubMed ID: 32853747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study.
    Tan HK; James PD; Wong F
    Dig Dis Sci; 2016 Oct; 61(10):3084-3092. PubMed ID: 27048451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MELD score and albumin replacement are related to higher costs during management of patients with refractory ascites.
    Borges de Santana V; Bertocco de Paiva Haddad L; Morgado Conte T; Cortez Rizzon A; Miranda Barbosa V; Shield W; Andraus W; Augusto Carneiro D'Albuquerque L
    Transplant Proc; 2014; 46(6):1760-3. PubMed ID: 25131030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albumin: Indications in chronic liver disease.
    Tufoni M; Zaccherini G; Caraceni P; Bernardi M
    United European Gastroenterol J; 2020 Jun; 8(5):528-535. PubMed ID: 32213034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Albumin administration in patients with decompensated liver cirrhosis: a meta-analytic update.
    Ashour AA; Atta MA; Sadek KW; Obaid KR; Ashour MA; Ashour A; Danjuma MI; Doi SA; ElZouki AN
    Eur J Gastroenterol Hepatol; 2021 Apr; 33(4):479-486. PubMed ID: 32976190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term albumin treatment in patients with cirrhosis and ascites.
    Caraceni P; O'Brien A; Gines P
    J Hepatol; 2022 Jun; 76(6):1306-1317. PubMed ID: 35589252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of human serum albumin treatment in patients with cirrhotic ascites undergoing paracentesis: A systematic review and meta-analysis.
    Shrestha DB; Budhathoki P; Sedhai YR; Baniya R; Awal S; Yadav J; Awal L; Davis B; Kashiouris MG; Cable CA
    Ann Hepatol; 2021 Dec; 26():100547. PubMed ID: 34626828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail.
    Moreau R; Valla DC; Durand-Zaleski I; Bronowicki JP; Durand F; Chaput JC; Dadamessi I; Silvain C; Bonny C; Oberti F; Gournay J; Lebrec D; Grouin JM; Guémas E; Golly D; Padrazzi B; Tellier Z
    Liver Int; 2006 Feb; 26(1):46-54. PubMed ID: 16420509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study.
    Yosry A; Soliman ZA; Eletreby R; Hamza I; Ismail A; Elkady MA
    Eur J Gastroenterol Hepatol; 2019 Mar; 31(3):345-351. PubMed ID: 30312183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised clinical trial: palliative long-term abdominal drains vs large-volume paracentesis in refractory ascites due to cirrhosis.
    Macken L; Bremner S; Gage H; Touray M; Williams P; Crook D; Mason L; Lambert D; Evans CJ; Cooper M; Timeyin J; Steer S; Austin M; Parnell N; Thomson SJ; Sheridan D; Wright M; Isaacs P; Hashim A; Verma S
    Aliment Pharmacol Ther; 2020 Jul; 52(1):107-122. PubMed ID: 32478917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL - a randomised clinical biomarker validation trial.
    Torp N; Israelsen M; Coenraad M; Papp M; Shawcross D; Korenjak M; Angeli P; Laleman W; Juanola A; Gines P; Trebicka J; Krag A;
    BMJ Open; 2024 Feb; 14(2):e079309. PubMed ID: 38355195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.
    Ginès P; Uriz J; Calahorra B; Garcia-Tsao G; Kamath PS; Del Arbol LR; Planas R; Bosch J; Arroyo V; Rodés J
    Gastroenterology; 2002 Dec; 123(6):1839-47. PubMed ID: 12454841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palliative long-term abdominal drains versus repeated drainage in individuals with untreatable ascites due to advanced cirrhosis: study protocol for a feasibility randomised controlled trial.
    Macken L; Mason L; Evans C; Gage H; Jordan J; Austin M; Parnell N; Cooper M; Steer S; Boles J; Bremner S; Lambert D; Crook D; Earl G; Timeyin J; Verma S
    Trials; 2018 Jul; 19(1):401. PubMed ID: 30053891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis.
    Ginès P; Titó L; Arroyo V; Planas R; Panés J; Viver J; Torres M; Humbert P; Rimola A; Llach J
    Gastroenterology; 1988 Jun; 94(6):1493-502. PubMed ID: 3360270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis.
    China L; Freemantle N; Forrest E; Kallis Y; Ryder SD; Wright G; Portal AJ; Becares Salles N; Gilroy DW; O'Brien A;
    N Engl J Med; 2021 Mar; 384(9):808-817. PubMed ID: 33657293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the evidence support a survival benefit of albumin infusion in patients with cirrhosis undergoing large-volume paracentesis?
    Bernardi M; Caraceni P; Navickis RJ
    Expert Rev Gastroenterol Hepatol; 2017 Mar; 11(3):191-192. PubMed ID: 28004601
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.